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A. TREATMENT OF VARIOUS SKIN DISEASES
ACTH (Armour) in the usually employed therapeutic doses has been used by
our group for the therapy and study of 44 patients representing 19 different
dermatoses. There were 29 cases representing 9 diseases which had previously
been reported by other investigators as responding favorably to ACTH therapy.
(1—19) The responses in our cases among these diseases were as follows:
1. Acute disseminated lupus erythematosus
F. W., female Negro, age 48, who had the disease for 6 months, had a good
response to therapy with 75—100 mgm. a day in 4 divided doses with disappear-
ance of edema, fever, arthralgia and malaise. The skin lesions have improved
slowly but the sedimentation rate has remained elevated. She has received ACTH
for 3 months and it is being continued.
Y. G., female, age 37, who had the disease for 3 months had a good response
to therapy with 100 mgm. per day for 15 days. The skin eruption disappeared,
and temperature and sedimentation rate dropped to normal. There has been no
remission in the 3 weeks since ACTH was discontinued.
2A. Psoriatic erythroderma with arthritis
L. S., female, age 23, was bedridden for 1 years prior to ACTH therapy. This
patient has improved so much under ACTH therapy that she is now managing
her own household. She has been maintained on ACTH for almost 6 months
with no relapse of her dermatosis or arthralgia. (Fig. 1) The maintenance dose
is now 12.5 mgm. b.i.d.
Two additional cases also had a good response to ACTH therapy: H. S. has
been maintained on therapy for 2 months with no relapse; and the other (M. G.)
relapsed when therapy was discontinued.
2B. Psoriasis vulgaris
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H. G., male, age 33, had no beneficial effect on his plaque-type of psoriasis
after 7 days of 100 mgm. of ACTH per day, followed by 4 days of combined
therapy of 50 mgm. of ACTH plus 100 mgm. of Cortone (Merck) daily. This
patient suffers from the usual form of psoriasis with involvement of a relatively
small part of the body surface.
The same negative response occurred in 1 additional case treated with ade-
quate doses of ACTH for 10 days.
3. Atopic dermatitis
Three cases had a good response to ACTH in doses of 60—100 mgm. per day
in 4 divided doses, but relapsed soon after the drug was discontinued. Two other
cases had no response while receiving 32.5 mgm. of AOTH every 12 hours for
8 days.
4. Acroscierosis (seleroderma)
A. S., female, age 52, who had the disease for 13 years, has been maintained
with a single daily injection of ACTH in Adactar Vehicle 32 since 10/14/50,
following one week of therapy with ACTH in saline solution. She has had approxi-
mately a 40% improvement in the mobility of her skin. This change has been
significant enough to enable her to pursue an essentially normal life.
5. Exfoliative dermatitis due to various causes
All 4 patients treated with ACTH experienced a 75—100% reduction of ery-
thema, scaling and pruritus within 1 week, but relapsed immediately on cessation
of therapy, except for 1 patient (I. K.) who received maintenance doses. One
of these patients (L. S., male) developed a multiform erythematous eruption
with fever, malaise, arthralgia, etc. during ACTH therapy, which was apparently
due to an allergic sensitization to some component of the ACTH preparation.*
6. Hodgkin's disease of the skin
J. L., male, age 66, showed a good response to ACTH given in conjunction
with local therapy. Improvement continued after ACTH was discontinued but
two tumor-like lesions have recently developed on his back.
7. Leukemia cutis (lymphatic)
W. D., male, age 67, had a very good response to a 13-day course of 100 mgm.
ACTH per day. (Fig. 2). Two months later new cutaneous nodules and tumors
began to appear. One daily injection of 25 mgm. ACTH was then given on an
ambulatory basis. After 10 days there was no improvement in the patient's skin
eruption and general weakness, and he developed a streptococcal septicemia
with a marked leukopenia. ACTH was stopped and he improved on antibiotics
and blood transfusions during hospitalization. ACTH (100 mgm. per day) was
begun again 10 days after this second admission and was given for 2 weeks. The
patient's general improvement was dramatic, and the skin lesions began to
resolve again. At the end of 2 weeks of ACTH, he suddenly had a general col-
lapse and died. The only pathological findings on autopsy, aside from
* Amore detailed description of this case was presented by Dr. Gordon C. Sauer at the
Hypersensitivity Symposium of the Second Clinical ACTH Conference, December 8—9,
1050, Chicago, Illinois, and will be published in the proceedings of this conference.
(a)
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FIG. 1. Psoriatic erythroderma with ankylosed arthritis in patient L. S., female, age
23. (a) Before ACTH therapy. (b) No sealing after 2 weeks of ACTH therapy.
the leukemia, were a bronchopneumonia (he had no fever prior to death) and
enlarged adrenal glands.
8. Mycosis fungoides (tumor stage)
F. K., male, age 47, had the disease for 5 years. (Fig. 3.) On 100 mgm. ACTH
per day for 1 week, the tumors and infiltrations of the skin flattened out and
15
 
Pm. 2. Leukemia antis (lymphatic) in patient W. D., male, age 67. .(a) Before-ACrE
herapy. (b) Improvement two months after a IS-day course of ACrE therijy.
(a) (b)
Pie. 3. Mycosis fungoides (tumor stage) in patient P. K., male, age 47. (a) Before ACTE
therapy. (b) Regression of lesions 3 days after completion of a week's course of ACrE
therapy.
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many disappeared. The intense pruritus was greatly alleviated. One week after
the ACTH was stopped the pruritus returned and the lesions became prominent
again. Further ambulatory therapy with ACTH 25 mgm. per day had no bene-
ficial effect.*
B. S., female, age 37, showed no beneficial response to the daily dose of 100—
175 mgm. of ACTH given over a 13 day period.
9. Pemphigus
B. K., male, age 66, with pemphigus vulgaris, had many generalized bullae
for 5 weeks. These disappeared while receiving 100—150 mgm. of ACTH per day,
plus supportive, non-specific therapy. ACTH has now been continued on an
ambulatory basis for 6 months, in doses of from 75—100 mgm. per day, with no
relapse and no toxicity.
Two other cases with pemphigus vulgaris showed moderate improvement while
on large doses of ACTH, but their skin was never completely free of lesions.
When ACTH was discontinued they relapsed immediately, and 1 died 16 days
later. The other one (H. H.) subsequently showed only moderate response when
cortisone was given orally, but cleared completely when Naphuride was ad-
ministered in conjunction with the oral cortisone. It should be noted that these
three patients also received Naphuride® therapy before, during and/or after
ACTH therapy.
The fourth case (H. G., male, age 54) with pemphigus vulgaris did not im-
prove on ACTH, and has subsequently died. The fifth case (Y. M., female,
age 53) with pemphigus vulgaris showed only slight benefit from 2 courses of
ACTH 100 mgm. a day and 1 course of cortisone 200 mgm. orally a day.
S. Z., male, age 42, with pemphigus vegetans had moderate benefit with AOTH
100 mgm. daily for 2 months. There was a complete suppression in formation
of bullae but no change in the vegetating lesions. The patient is now receiving
100 mgm. of cortisone orally a day with no further change except that he has
developed a severe mental depression, moon-shaped face, and transient ankle
edema.
Two patients (A. M. and E. G.) with pemphigus foliaceus did not respond to
ACTH therapy of 100 mgm. per day for 20 and 25 days respectively.
In addition to the nine above-described conditions, in which our results gen-
erally confirm those of previous investigations, there were 10 other cutaneous
diseases in which ACTH was administered and which to our knowledge have not
previously been reported as having been treated with this material. They were
as follows:
1. Subacute disseminated lupus erythematosus
K. M., female, age 38. Erythematous petechial lesions of 5 weeks' duration
began to fade in 48 hours after ACTH was started. After 2 weeks of therapy to
* This case has been previously published (Tulipan (17) ) as a case of failure of ACTH
therapy in mycosis fungoides. The case is listed here as having benefited by ACTH since
the patient improved very significantly while receiving adequate doses of ACTH. A relapse
occurred only when inadequate doses were given or when the ACTH was discontinued.
(See Fig. 3).
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a total of 1 gram ofACTU, the drug was discontinued. There has been no recur-
rence in a 2-month period.
2. Chronic discoid lup'us erythematosus
E. C., female, age 34, had the disease for 7 years. (Fig. 4). ACTH therapy of
100 mgm. daily for 11 days resulted in marked fading of the lesions. Subse-
quently, the patient started to have a recurrence and received treatment with
vitamin C and a series of gold injections with no definite further improvement.
After 7 months the patient is still greatly improved over her condition before
ACTH therapy.*
R. C., female, age 46, had the disease for 10 years. On 50—100 mgm. of ACTH
daily for 3 weeks the discoid lesions faded. Within 1 week after cessation of ther-
apy the lesions relapsed. She was then started on oral cortisone therapy which
also resulted in fading of the lesions. She is still on this therapy.
3. Distinctive exudative discoid and lichenoid chronic dermatosis (Sulzberger and
Garbe)
Two male patients had moderate benefit from ACTII therapy with lessening
of pruritus and healing of exudative lesions. One (E. B.) relapsed after main-
tenance therapy was discontinued and the other moved to Texas for climo-
therapy.
4. Nummular eczema
V. R., male, age 62, received considerable benefit from ACTH given in com-
bination with local therapy. After ACTH was discontinued he continued to
improve with local therapy.
5. Kaposi's multiple idiopathic hemorrhagic sarcoma
A. 0., male, age 58, had the disease for 11 years. After 12 days of ACTH
therapy ranging from 100—200 mgm. per day there was no response.
6. Reticulum cell sarcoma
C. G., female, age 39, had the disease for 3 years. ACTH therapy brought
about a definite flattening of the nodular cutaneous lesions. Therapy was con-
tinued in doses of from 100—150 mgm. daily for 33 days. Near the end of this
time the patient developed a toxic psychosis that disappeared soon after the
ACTH was discontinued. In addition, the site of an incision for drainage of an
abscess did not heal during the ACTH therapy. The skin lesions have remained
flattened on x-ray therapy.
J. 0., male, age 50, was not benefited by the usual therapeutic courses of
ACTII or cortisone.
7. Severe persistent neuralgic pain following gangrenous herpes zoster facialis
A. U., female, age 67, had severe pain for 1 month that persisted in spite of
therapy with Aureomycin, autoblood, Protamide, snake venom, Demerol and
placebos. Following 2 injections of 25 mgm. each of ACTH given at an interval
of 6 hours, the pain disappeared completely; but it was eventually found that
an ACTH injection of 12.5 to 25 mgm. given at 8—12 hour intervals would main-
tain her free of pain. After 28 days of intermittent therapy the ACTE injections
were stopped; slight pain recurred but was readily controlled with aspirin.
*L. E. Cells have been found in this patient's peripheral blood. Therefore this case
must now be considered one of subacute disseminated lupus erythematosus.
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(b)
Fjo. 4. Chronic discoid lupus erythematosus in patient B. C., female, age 34. (a) Before
ACTH therapy. (b) Improvement maintained at 5 months after end of ACTH therapy.
8. Lichen planus
D. C., female, age 52, had an intensely pruritie, generalized form of this disease
for over 6 months. She had not responded to the usual forms of therapy. On
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ACTH therapy of 75—100 mgm. per day there was regression of the skin lesions
in 3—5 days, with complete disappearance at the end of the 10 day course of
therapy. The pruritus dramatically improved and subsided within 5 days.
Within one week after therapy was stopped, the lesions and pruritus began to
recur. The patient is now on ambulatory oral cortisone therapy.
9. Sarcoidosis (Boeck)
H. L., female, age 32, showed a moderate diminution in the induration of the
lesions on 100 mgm. of ACTH per day for 11 days. Sufficient time has not
elapsed for further evaluation of her response.
10. Dermatitis her pet if ormis
I. H., female, age 52, had the eruption for 12 years. On 60 mgm. per day of
ACTH (Wilson and Co.) there was only a slight improvement, but when the dose
was raised to 100 mgm. a day the intense pruritus and vesicles disappeared.
Two other cases* were not benefited by ACTH therapy of 100 mgm. per day.
SIDE EFFECTS
Side effects of ACTH treatment occurred in 22 of 44 patients and included:
(1) increased localized or generalized pigmentation in 12 cases;
(2) moon-shaped facies in 9 cases;
(3) hyperglycemia in 2 cases;
(4) mild furunculosis in 1 case;
(5) ankle edema in 4 cases;
(6) toxic psychosis (transitory) in 2 cases; and
(7) a multiform erythematous eruption (allergic?) with fever, malaise, etc. in
1 case.
AMBULATORY TREATMENT
ACTH administrations were continued on an ambulatory basis in 7 of our
patients following their improvement in the hospital. The beneficial effects were
maintained in 6 cases with varying doses of ACTH given in the usual solution
twice daily, or with ACTH in Adactar Vehicle 32 given once a day, to patients
with psoriatic erythroderma with arthritis (IL. S.), acrosclerosis (A. S.), ex-
foliative dermatitis (I. K.), Hodgkin's disease of the skin (J. L.), pemphigus
vulgaris (B. K.), and dermatitis herpetiformis (I. H). In the patient with
distinctive exudative discoid and lichenoid chronic dermatosis (E. B.) only a
fair degree of improvement could be maintained with the usual therapeutic
doses of ACTH.
EFFECT OF ACTH ON WOUND HEALING
Ten out of 13 skin incision biopsies taken during the course of ACTH therapy
or 1—2 days prior to institution of therapy healed normally. It was our impression
that the delay in healing of the other 3 biopsy wounds was not necessarily due
to ACTH but was probably due to extraneous factors. On the other hand, deeper
surgical incisions made for draining abscesses in 2 patients failed to heal during
* The diagnosis of dermatitis herpetiformis was not established beyond doubt in these
2 cases.
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ACTH therapy, but healed promptly when ACTU was discontinued. It is our
impression that epithelial growth and healing are normal under ACTH adminis-
tration, while dermal and connective tissue repair is retarded or inhibited.
B. COMPARISON OF EFFECTS OF ACTH AND SUBSTANCES WITH
PRESUMED RELATED ACTION
Desoxycorticosterone acetate (Roche-Organon) and ascorbic acid were given
by the method of Lewin and Wassin to 1 patient each with psoriasis and arthri-
tis, pemphigus vulgaris, Hodgkin's disease of the skin and atopic dermatitis.
There were no beneficial effects from the Lewin and Wassin combination, al-
though all these cases responded to ACTH therapy when administered either
before or subsequently.
Pregnenolone (Schering), lipo-adrenal cortical extract (Upjohn), and hydroxy-
phenyl-cinchoninic acid (Squibb) also produced no beneficial effects in the
patient with psoriasis and arthritis (L. S.) who responded well to ACTH.
C. EFFECTS OF ACTH ON VARIOUS PHYSIOLOGIC FUNCTIONS OF THE SKIN
These studies are still in progress and we here present merely the trends thus
far observed and the possible inferences from these trends. In other words, due
to the small number of observations to date, one can hardly speak yet of "re-
suits".
The studies were carried out in ten of the previously enumerated patients with
different skin diseases. While in individual cases the dosage varied slightly, the
average dosage was 25 mgm. of ACTH four times a day, injected intramuscularly
for seven to ten days. The examinations were carried out before, as well as
during and after (usually two to seven days after) the end of the course. However,
it was not possible to repeat all the 7 different types of examinations listed
below in every patient both during and after the treatment. (Cf. Table 1)
1. Intracutaneous Injection of Equilibrated Saline Solution for Determination of
the Wheal Absorption Time (McClure-Aldrich Test).
The absorption time of the wheal produced by intracutaneous injection of
saline solution was distinctly shortened during ACTH treatment in 7 of 10, and
after the treatment in 8 of 10 patients investigated.
This might be explained by increased hydration capacity of the collagen, or by enhanced
peripheral circulation, or perhaps by a combined effect of both these changes.
2. Measurements of the Skin Temperature of Healthy and Diseased Areas of the
Skin under Different Standardized Conditions. *
The readings of the skin temperature showed a trend to elevation in 7 of 9
patients during the administration of ACTH; 2 days after the treatment, return
of the elevated readings to the original level was observed in 1 of the subjects
investigated.
* (The examinations listed under 2, 3 and 4 above, were carried out in each patient in a
considerable number of tests performed on a series of selected skin areas which were the
same in every test and individual.)
t The Thermocouple UMA, Inc., New York City, was employed.
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The cause of the trend to elevated skin temperatures may be an increased activity of the
peripheral circulation.
3. Quantitative Estimations of the Delivery of Sweat to the Skin Surface in Re-
sponse to Dry Heat, Employing Brom-Phenol Blue at Alkalinity as a Color
Indicator.
This indicator was recently introduced at W. Jadassohn's institute by B.
Boymond (20) and L. Manuila (21) for testing sweat delivery; and was used in
TABLE I
OBJECT OF EXAMINATION
OBSERVATIONS IN 10 PATIENTS COMPARED WITH THE FINDINGS
PRIOR TO TREATMENT WITH ACTH (100 MG. DAILY FROM 7—10 DAYS)
Result
Number of Patients
.
During
treatment
After
treatment
Absorption-Time of Saline Wheal
(McClure-Aldrich test)
greatly decreased
greatly prolonged
uncertain
Koebner phenomenon
7
1*
1
if
8
1
—
1
Skin Temperature (Multiple test
sites on clinically unaffected & on
diseased skin)
elevated
slightly elevated
unchanged
decreased
not investigated
5
2
1
1
1
4
1
2
1
2
Sweat Delivery increased
slightly increased
unchanged
decreased
slightly decreased
not investigated
3
1
3
1
2
—
4
—
3
—
3
Quantity of Ether-Soluble Film
(Sebum, etc.)
increased
decreased
slightly decreased
unchanged
not investigated
—
7
1
2
—
2
5
—
2
1
* Leukemia Cutis (lymphatic); absorption-time very short prior to ACTH
t Pemphigus vulgaris
Generalized Dermatitis Exfoliativa
our laboratories for elaborating a quantitative method which will be published
shortly.
Sweat delivery in a considerable number of test areas was distinctly increased
in 2; slightly increased in 2; distinctly decreased in 1; slightly decreased in 2;
unchanged in 2; and not investigated in 1 of the 10 patients during the treat-
ment. After termination of ACTH administration, the outpouring was still
distinctly increased in 1, slightly increased in 2, slightly decreased in 1, and the
same as before the course of treatment in 3 of 7 examined cases.
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Hypothetically, the observed trend to increased sweat delivery to the skin surface might
be due to stronger electronegativity at the end portion of the sweat ducts, with resulting
increase in the electrophysiologic potential along the ducts which presumably facilitates
the outpouring (22) (23).
4. Quantitative Assays of the Amount and Replacement of Ether-Soluble Sub-
stances (Sebum, etc.) on the Skin.
The levels of ether-soluble substances on the skin as measured by a recently
developed technic (24) showed a tendency to decline in 8 of 10 patients during
the treatment with ACTH. In 5 of these 8 subjects, the levels after treatment
remained below those obtained before the administration of ACTH, whereas 2
subjects showed an increase in the amounts over the original levels.
In theory, the decline of the levels of ether-soluble material on the skin might be caused
by stimulation of a cerebral center in the diencephalon, to which an inhibiting influence
on the production of the sebaceous material has been attributed.
5. Observation of the Blood Capillaries through the Stereoscopic Wide-Field
Microscope.
An increased number of visible capillaries, narrowing of the afferent parts of
the capillary end-loops, and accelerated blood flow through the capillaries were
observed in 5 of 7 subjects during, and in 4 of 6 subjects after the administration
of the drug. In 1 patient, evaluation was impossible for technical reasons.
The changes are suggestive of accelerated peripheral circulation under the influence of
AUTH.
6. Studies of the Staining Affinity of the Spiral Portion of the Sweat Ducts for
Electropositive Dyes, Especially for Atabrine (Mepacrine Hydrochloride).
Observations obtained in situ through the employment of the wide-field micro-
scope (22, 23) showed a tendency to increased staining intensity of the spiral
part of the sweat ducts. This increased staining was seen in 5 of 8 subjects during
treatment; and in half the number of the patients investigated shortly after the
treatment.
Since electropositive dyes were employed, the observation of intensified staining may
lend support to the concept of increased electronegativity at the end portion of the ducts
under AUTH therapy (22, 23).
7. Fluorescence—Examinations of the Skin under Filtered Ultraviolet Radiation
after Intravenous Injection of Sodium Fluoresceim.
The fluorescence pattern of the skin under filtered ultraviolet radiation after
intravenous injection of sodium fluorescein showed changes in consonance with
the changes in the clinical conditions. When a delay was noted in the onset of
fluorescence of clinically unaffected skin prior to the administration of AUTH,
this delay was generally reduced during and after administration of ACTH.
Moreover, the hyperfluorescence of affected areas was reduced more quickly and
more conspicuously after treatment with ACTH than before such treatment (25).
These manifestations of accelerated exchange of the dye between the extravascular
and the intravascular spaces of the skin might be explained by enhanced peripheral circu-
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lation; or by increase of the effective partial pressures of concentration of dye; but could
also result from increased capillary permeability and certain other factora.
D. IMMUNOLOGIC CHANGES
While here also the series is still much too small to be conclusive, the following
trends were noted in the present preliminary observations of 10 patients.
(1) In 2 out of 5 patients who had positive tuberculin reactions prior to therapy
the reactions to intracutaneous injections of O.T.K. were decreased during or
following AUTH therapy in the doses specified (100 mgm. daily for 7 to 10 days).
Of 3 patients who had negative tuberculin tests before AUTH administration, 2
had positive reactions after therapy in the specified doses.
These results suggest that ACTH administration may be capable of producing
a change in the skin's capacity to react to tuberculin and that this change may
be in either direction.
(2) Patch tests with poison ivy and paraphenylenediamine in 7 patients who
were negative before AUTH showed no significant change during and after
AUTH administration in the specified doses. One patient who had evidenced a
4 plus positive reaction to poison ivy before, showed a weaker reaction during
and shortly after the course of administration of ACTH. However, two patients
with strongly positive reactions to paraphenylenediamine and leather materials
respectively, showed essentially the same reactions while under AUTH therapy
as they had had before start of therapy.
These results suggest that AUTH does not consistently influence or reduce the
patch test responses to eczemato genie allergens.
(3) Skin tests for allergic immediate urticarial reactions to intracutaneous in-
jections of ragweed and dust showed no significant changes during or after
treatment in 9 patients who were negative or positive before AUTH. These
results suggest that AUTH in the doses here given does not influence or reduce the
wheat response to skin tests with urticario genie allergens.
E. SKIN RESPONSES TO PRIMARY IRRITANTS
(1) In the 7 persons tested, primary irritation of the skin of eczematoid and
er'ythematous p4—48 hour type, due to 1/10% anthralin ointment, was not in-
fluenced by the administration of AUTH.
(2) There was also no observable influence of AUTH on the immediate wheat
produced by a non-allergenic primarily urticariogenic agent (histamine) in 8 cases.
These results suggest that AUTH in the doses here given does not consistently
influence or reduce the primary irritant eczematoid or urticarial reaction.
F, SUMMARY
A. Forty-four patients representing 19 different dermatologic conditions were
treated with average doses of AUTH (approximately 100 mgm. daily in 4 di-
vided doses). Beneficial effects of varying degree were obtained in patients with
lupus erythematosus of the acute (2 cases), subacute (1 case), and chronic dis-
coid (2 cases) types; psoriatic erythroderma with arthritis (3 cases); atopic
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dermatitis (3 cases): acroscierosis (1 case); exfoliative dermatitis due to various
causes (4 cases); Hodgkin's disease of the skin (1 case); leukemia cutis (1 case);
mycosis fungoides (1 case); pemphigus vulgaris (3 cases); exudative discoid and
lichenoid chronic dermatosis (2 cases); nummular eczema (1 case); reticulum
cell sarcoma (1 case); severe persistent neuralgic pain following gangrenous
herpes zoster facialis (1 case); lichen planus (1 case); sarcoidosis (Boeck) (1
case), and dermatitis herpetiformis (1 case).
There was no essential beneficial effect with the specified dosage in patients
with psoriasis vulgaris (2 cases); mycosis fungoides (1 case); pemphigus vulgaris
(2 cases); pemphigus vegetans (1 case); pemphigus foliaceus (2 cases); reticulum
cell sarcoma (t case); Kaposi's multiple idiopathic hemorrhagic sarcoma (1 case),
and dermatitis herpetiformis (2 cases). Inadequate therapy was given to 2 cases
of atopic dermatitis with no benefit.
Maintenance therapy was carried out with good results in 6 cases.
Relapses of varying degrees occurred in almost all of the other patients after
AUTH treatment had been discontinued.
B. Other substances with presumed action related to ACTH (excluding cor-
tisone) were found to have no effect even in cases proved to be benefited by
AUTH therapy.
C. Investigations of various physiologic functions of the skin were carried
out before, during and after the administration of ACTH. The investigations at
this time are not sufficiently extensive to permit the drawing of conclusions, but
thus far the following trends have been noted to result from the administration:
1. The absorption time of intradermally injected saline solution (McClure-
Aldrich test) tended to be abbreviated.
2. The skin temperature showed a tendency to elevation.
3. The delivery of sweat was more frequently augmented than decreased in
the tests in which changes were noticeable.
4. The amount of ether-soluble material (sebum plus other substances soluble
in ether) was distinctly diminished in most instances.
5. Studies of the blood capillaries suggested a trend toward accelerated peripheral
flow.
6. Examinations in vivo showed that the spiral portion of the sweat ducts
showed a tendency to increased staining affinity for electropositive dyes.
D. Immunologic studies in a small series of cases tested before, during and
after ACTH administration were:
(1) inconclusive with regard to the tuberculin-type reaction;
(2) ACTH did not significantly change the patch test response to eczemato-
genic allergens; nor
(3) the wheal response to intracutaneous tests with urticariogenic allergens.
E. ACTH, in the small series studied, also had no influence on the non-im-
munologic skin reactions: (1) of the eczematoid and erythematous type pro-
duced by primary irritants or (2) the immediate wheal reaction produced by a
non-allergenic primary urticariogenic agent.
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